Clearmind Medicine (CMND) Long-Term Deferred Tax (2021 - 2022)
Clearmind Medicine (CMND) posted quarterly Long-Term Deferred Tax of $203648.4 for Q4 2022, down 74.46% year-over-year from $797380.2 in Q4 2021, and down 74.46% quarter-over-quarter from $797380.2 in Q4 2021.
Clearmind Medicine (CMND) Long-Term Deferred Tax (2021 - 2022) Analysis & Trends
Clearmind Medicine's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $203648.4 for Q4 2022.
- In Q4 2022, Long-Term Deferred Tax fell 74.46% year-over-year to $203648.4; the TTM figure through Oct 2022 stood at $203648.4 (down 74.46% YoY), while the FY2022 annual figure was $198173.0, down 75.14% from the prior year.
- Long-Term Deferred Tax for Q4 2022 stood at $203648.4, down from $797380.2 in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $797380.2 in Q4 2021, with the low at $203648.4 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Clearmind Medicine | 540,485.35 | -13.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2022 | 203,648.43 |
| Oct 31, 2021 | 797,380.23 |